ABBV vs PYPL: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and PayPal Holdings, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-17.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
PayPal Holdings, Inc. · Financial Services
$52.71
+9.1% upside to fair value
Med Conviction
Grade B-
QuantHub Verdict
PYPL has more upside to fair value
(+9.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PYPL |
| Current Price |
$261.70 |
$52.71 |
| Fair Value Estimate |
$259.04 |
$57.50 |
| Upside to Fair Value |
-1.0%
|
+9.1%
|
| Market Cap |
$462.4B |
$45.1B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
6.8x
|
| Price / Sales |
7.2x
|
1.3x
|
| Price / FCF |
23.6x
|
7.2x
|
| Revenue Growth YoY |
+10.2%
|
+4.8%
|
| Gross Margin |
71.5%
|
45.8%
|
| Operating Margin |
29.3%
|
18.8%
|
| Return on Equity |
-136.5%
|
24.4%
|
| Dividend Yield |
2.61% |
1.06% |
| FCF Yield |
4.25%
|
13.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
PayPal operates a global digital-payments platform spanning branded checkout, Venmo, Braintree merchant processing, credit products and fraud-risk infrastructure across approximately 200 markets. Business quality is medium: its two-sided network, trusted brand, broad merchant distribution and risk capabilities remain meaningful assets, but its highest-value branded-checkout franchise is under com…
Accumulation Zones
| Metric |
ABBV |
PYPL |
| Zone Low |
$194.28 |
$43.12 |
| Zone High |
$220.18 |
$48.88 |
| In Buy Zone? |
No
|
No
|